Document Detail


Effect of prolonged ingestion of gamma-linolenate by MS patients.
MedLine Citation:
PMID:  631143     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The absolute electrophoretic mobility of erythrocytes from MS patients is reduced in the presence of 0.08 mg/ml of linoleic or arachidonic acid, whilst that of normal or other neurological disease patients is increased in the presence of these acids. When an MS patient ingests gamma-linolenate (in capsule form equivalent to 413.4 mg of gamma-linolenic acid and 2.664 g of linoleic acid per day) the reaction of MS erythrocytes begins to change. After 3 or 4 months the reaction becomes normal with arachidonic acid (i.e. mobility is speeded up) and 2 months or so later this occurs also with linoleic acid. Very prolonged administration of gamma-linolenate leads to a markedly increased sensitivity to the effect of prostaglandins (PGE2) on RBC mobility. The observations are interpreted to mean the induction of a biochemical-biophysical change in the membranes, and the significance of this in the aetiology and treatment of multiple sclerosis is discussed.
Authors:
E J Field; G Joyce
Related Documents :
198993 - Enzymatic oxydation of linoleic acid: formation of bittertasting fatty acids.
754503 - Comparative fatty acid composition of lipids from tubular and interstitial cells of rat...
10715593 - A comparison of extrahepatic lipogenesis from a small glucose meal in obob and gold thi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European neurology     Volume:  17     ISSN:  0014-3022     ISO Abbreviation:  Eur. Neurol.     Publication Date:  1978  
Date Detail:
Created Date:  1978-05-08     Completed Date:  1978-05-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0150760     Medline TA:  Eur Neurol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  67-76     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Arachidonic Acids / therapeutic use
Electrophoresis
Erythrocyte Membrane / drug effects
Erythrocytes / drug effects*
Female
Humans
Infant
Linoleic Acids / therapeutic use
Linolenic Acids / therapeutic use*
Male
Middle Aged
Multiple Sclerosis / blood,  drug therapy*
Time Factors
Chemical
Reg. No./Substance:
0/Arachidonic Acids; 0/Linoleic Acids; 0/Linolenic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relapsing polyradiculitis after portocaval anastomosis.
Next Document:  Continent ileostomy. A pilot study in dogs.